Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Larry W Kwak Luis E. Fayad Michelle A Fanale Anas Younes Amanda R Copeland Sattva S Neelapu Jorge Romaguera Fredrick B Hagemeister Leo Gordon |
| Publication date | July 2, 2012 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |